Patient-Reported Barriers and Facilitators to Deprescribing Cardiovascular Medications.

ABSTRACT:

Background

Medications endorsed by clinical practice guidelines, such as cardiovascular medications, could still have risks that outweigh potential benefits, and could thus warrant deprescribing.

Objectives

The objective of this study was to develop a framework of facilitators and barriers specific to deprescribing cardiovascular medications in the setting of uncertain benefit. Given the frequent use of β-blockers in heart failure with preserved ejection fraction, and its uncertain benefits with potential for harm, we used this scenario as an example case for a cardiovascular medication that may be reasonable to deprescribe.

Methods

We conducted one-on-one, semi-structured interviews of older adults until we reached thematic saturation. Two coders independently review

SUBMITTER: Goyal P 

PROVIDER: S-EPMC7339041 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature